Australia markets open in 4 hours 17 minutes
  • ALL ORDS

    7,114.50
    -133.60 (-1.84%)
     
  • AUD/USD

    0.7030
    -0.0090 (-1.27%)
     
  • ASX 200

    6,838.30
    -123.30 (-1.77%)
     
  • OIL

    86.73
    -0.62 (-0.71%)
     
  • GOLD

    1,792.80
    -36.90 (-2.02%)
     
  • BTC-AUD

    51,406.97
    -2,674.41 (-4.95%)
     
  • CMC Crypto 200

    826.17
    +6.67 (+0.81%)
     

CORRECTING and REPLACING CASSAVA SCIENCES ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cassava Sciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • SAVA

NEW YORK, December 04, 2021--(BUSINESS WIRE)--Second paragraph of release dated December 3, 2021, should read: The lawsuit alleges that... (instead of The complaint, filed on January 5, 2021, alleges that...)

The updated release reads:

CASSAVA SCIENCES ALERT: BRAGAR EAGEL & SQUIRE, P.C. IS INVESTIGATING CASSAVA SCIENCES, INC. ON BEHALF OF LONG-TERM STOCKHOLDERS AND ENCOURAGES INVESTORS TO CONTACT THE FIRM

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (NASDAQ: SAVA) on behalf of long-term stockholders following a class action complaint that was filed against Cassava Sciences on August 27, 2021. Our investigation concerns whether the board of directors of Cassava Sciences have breached their fiduciary duties to the company.

The lawsuit alleges that, throughout the Class Period, defendants made false and misleading statements and failed to disclose that: (i) the quality and integrity of the scientific data supporting Cassava Sciences’ claims for simufilam’s efficacy had been overstated; (ii) the scientific data supporting Cassava Sciences’ claims for simufilam’s efficacy were biased; and (iii) as a result, defendants’ positive statements during the Class Period about Cassava Sciences’ business metrics and financial prospects and the likelihood of U.S. Food Drug Administration ("FDA") approval were false and misleading and/or lacked a reasonable basis.

If you are a long-term stockholder of Cassava Sciences, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Alexandra B. Raymond by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005590/en/

Contacts

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting